Startseite Evaluation of Five Commercial Enzyme Immunoassays for the Detection of Human Cytomegalovirus-Specific IgM Antibodies in the Absence of a Commercially Available Gold Standard
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Evaluation of Five Commercial Enzyme Immunoassays for the Detection of Human Cytomegalovirus-Specific IgM Antibodies in the Absence of a Commercially Available Gold Standard

  • Bernd Genser , Martini Truschnig-Wilders , Doris Stünzner , Maria Paola Landini und Gabriele Halwachs-Baumann
Veröffentlicht/Copyright: 1. Juni 2005
Veröffentlichen auch Sie bei De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Band 39 Heft 1

Abstract

In the recent years the number of commercially available immunoassays for the detection of human cytomegalovirus (HCMV)–specific immunoglobulin M (IgM) antibodies has rapidly increased. The aim of the present study was to evaluate five commercial immunoassays for the serological diagnosis of HCMV-infection. These methods, namely the IMx CMV IgM assay, the AxSYM CMV IgM assay (both Abbott), the Gull CMV IgM, the CMV-IgM-ELA test PCS Medac and the Biotest Anti-HCMV recombinant IgM ELISA, were compared for their diagnostic effectiveness and interference with substances eventually producing cross-reactions with HCMV-IgM (Epstein-Barr-virus (EBV)-IgM, rheumatoid factor (RF)). In addition, repeated measurements on samples from kidney and heart transplant recipients with active HCMV infection were examined to compare the temporal development of the HCMV-IgM measured with the five assay systems. Since there is no commercially available gold standard, it was assumed that the true classification, of whether the patient sample is HCMV-IgM positive or negative, was unknown. Hence sensitivity and specificity were assessed based on a maximum likelihood approach using a “latent class” model. The cross-reactions were quantified by a Bayesian statistical model using prior information for the expected prevalences in the EBV-IgM and rheumatoid factor sample groups. The results of the study demonstrated that there are great differences in sensitivity and specificity as well as in cross-reactions with EBV-IgM and RF between the tested ELISAs.

:
Published Online: 2005-06-01
Published in Print: 2001-02-21

Copyright (c) 2001 by Walter de Gruyter GmbH & Co. KG

Artikel in diesem Heft

  1. Editorial
  2. Polymorphisms in the Apolipoprotein E Gene Regulatory Region in Relation to Coronary Heart Disease and Their Effect on Plasma Apolipoprotein E
  3. Further Characterization of Serum Amyloid A4 as a Minor Acute Phase Reactant and a Possible Nutritional Marker
  4. Determination of Human Angiotensin Converting Enzyme (ACE) Gene Polymorphisms in Erectile Dysfunction: Frequency Differences of ACE Gene Polymorphisms according to the Method of Analysis
  5. Simple Gas Chromatography Analysis of Faecal Butyrate: Application to Patients at Risk of Pouchitis
  6. Determination of Glycerol in Plasma by an Automated Enzymatic Spectrophotometric Procedure
  7. Clinical Applications of the 2nd Generation Assay for Anti-TSH Receptor Antibodies in Graves' Disease. Evaluation in Patients with Negative 1st Generation Test
  8. The Clinical Value of Microtransferrinuria and Microalbuminuria in the Prediction of Pre-eclampsia
  9. A Non-Icteric Cholecystectomized Patient with Recurrent Attacks of Right Epigastric Pain and Dilated Common Bile Duct – Do Liver Function Tests Predict Bile Duct Stones?
  10. Serum Lactate Dehydrogenase Isoenzyme 1 and Prediction of Death in Patients with Metastatic Testicular Germ Cell Tumors
  11. Annual Rhythmic and Non-Rhythmic Biological Variation of Magnesium and Ionized Calcium Concentrations
  12. Unit-Independent Reporting of Laboratory Test Results
  13. Analysis of Large and Small Samples of Biochemical and Clinical Data.
  14. Evaluation of Five Commercial Enzyme Immunoassays for the Detection of Human Cytomegalovirus-Specific IgM Antibodies in the Absence of a Commercially Available Gold Standard
  15. Alkaline Phosphatase Activity: New Assay for the Reflotron® System. Results of the Evaluation in Eight Clinical Laboratories
  16. Report on the 4th Estonian Summer School of Laboratory Medicine
  17. Laboratory-Related Measures of Patient Outcomes: An Introduction. Edited by Michael G. Bissell
  18. Report from the 50th Anniversary Congress of the Hungarian Society of Clinical Pathology and from the Executive Board Meeting of FESCC in Debrecen (Hungary)
  19. Report from the 8th Meeting of the Balkan Clinical Laboratory Federation
Heruntergeladen am 26.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2001.014/html?lang=de
Button zum nach oben scrollen